Bispecific antibodies in multiple myeloma: Opportunities to enhance efficacy and improve safety
Last Updated: Wednesday, September 20, 2023
Bispecific antibodies (BsAbs) represent a new treatment option for patients with multiple myeloma, even in high-risk and heavily pretreated patients. This review considers ways to improve the activity of these new BsAb therapies, as well as ways to reduce the risk of serious side effects, including cytokine release syndrome.
Advertisement
News & Literature Highlights